Eurofins Scientific has been granted a patent for a method to detect cell-free DNA from specific cell types in biological samples, aiding in diagnosing conditions like preeclampsia and cancer. The patent also covers a computer program product for managing operations related to DNA analysis. GlobalData’s report on Eurofins Scientific gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Eurofins Scientific, Telomerase reverse transcriptase screening was a key innovation area identified from patents. Eurofins Scientific's grant share as of May 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Prenatal diagnosis of medical conditions using dna methylation
A recently granted patent (Publication Number: US11965207B2) discloses a computer program product designed to control a computing system to determine the presence of a medical condition in an individual or the potential for a DNA anomaly in a fetus. The product involves receiving signals related to methylation levels at differentially methylated regions (DMRs) in a sample from a pregnant female, as well as the total amount of DNA in the sample. By comparing these signals and analyzing the relative or absolute amount of DNA originating from the fetus or placenta cells, the system can identify medical conditions or anomalies, such as chromosomal trisomy, in the fetus.
Furthermore, the patent includes steps for determining the absolute amount of DNA in the sample, specifying that the DNA species in question is circulating cell-free DNA found in plasma or serum samples. The system can also identify an increased risk of pregnancy-associated medical conditions like preeclampsia, preterm labor, intrauterine growth retardation, or vanishing twin by analyzing the DNA species fraction. The method utilizes specific regions or genes for quantification, such as those listed in the patent, and employs multiplex real-time quantitative probe-based PCR for accurate quantification of DNA regions. Overall, the patented computer program product offers a sophisticated and precise method for detecting medical conditions and DNA anomalies in fetuses based on methylation levels and DNA quantification in pregnant individuals.
To know more about GlobalData’s detailed insights on Eurofins Scientific, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
